Management of Triple-Negative Breast Cancer

Early-Stage TNBC (Stages I-III)

• The American College of Surgeons recommends dose-dense anthracycline and taxane combinations as the standard neoadjuvant approach for stage II-III disease, achieving pathological complete response rates exceeding 20% 1
• For very small tumors (<5 mm, stage I), surgical excision alone may be appropriate, though nearly half of experts still recommend adjuvant chemotherapy even for these minimal tumors 1
• Sentinel lymph node biopsy is standard for clinically node-negative patients at initial presentation 1
• For patients with clinically positive nodes who receive neoadjuvant chemotherapy, sentinel lymph node biopsy may be considered if nodes become clinically negative after treatment 1
• Axillary lymph node dissection is recommended for residual nodal disease after neoadjuvant therapy, especially for macrometastases >2mm 1
• Post-mastectomy radiation should be considered for patients with positive lymph nodes or positive/close margins 1
• Post-lumpectomy radiation to the breast is standard after breast-conserving surgery, as recommended by the American Society for Radiation Oncology 2
• For patients with germline BRCA1/2 mutations and high-risk early-stage TNBC, adjuvant olaparib for 1 year should be considered 1
• Do not routinely recommend prophylactic contralateral mastectomy based solely on TNBC status; this should only be considered for patients with germline BRCA1/2 mutations, young age, or strong family history, as advised by the American Society of Clinical Oncology 1

Metastatic TNBC

• For PD-L1-positive metastatic TNBC (CPS ≥10), the National Comprehensive Cancer Network recommends immune checkpoint inhibitor plus chemotherapy as the first-line therapy, with improved progression-free survival compared to chemotherapy alone 3, 4
• For PD-L1-negative disease, single-agent chemotherapy is preferred for first-line treatment to minimize toxicity, as suggested by the European Society for Medical Oncology 3, 4
• Combination chemotherapy may be offered only for symptomatic or immediately life-threatening disease where time may allow only one potential chance for therapy 3, 4
• Taxanes are preferred first-line options if not previously used in the adjuvant setting, according to the American Society of Clinical Oncology 4
• Anthracyclines are recommended if not previously administered, as recommended by the National Comprehensive Cancer Network 4
• Platinum agents with or without taxanes are appropriate options, with selection based on individual risk-benefit assessment, recognizing increased toxicity including nausea, vomiting, and anemia, as advised by the European Society for Medical Oncology 3, 4
• For patients who have received at least two prior therapies for metastatic disease, sacituzumab govitecan is strongly recommended, with significant improvements in both progression-free survival and overall survival, as recommended by the American Society of Clinical Oncology 3, 4
• For patients with germline BRCA1/2 mutations, oral PARP inhibitors are recommended rather than chemotherapy in the first-through third-line setting, as suggested by the National Comprehensive Cancer Network 3, 4
• Patients receiving checkpoint inhibitors must be monitored closely for immune-related adverse events, which can affect any organ system, as advised by the European Society for Medical Oncology 4
• Bevacizumab combined with chemotherapy has shown improved progression-free survival but not overall survival, limiting its routine recommendation, as recommended by the American Society of Clinical Oncology 4

Management of Triple-Negative Breast Cancer

Diagnosis and Assessment

• The European Society for Medical Oncology recommends confirming triple-negative status via biopsy with complete pathologic assessment including histological grade and Ki67 markers 5, 6
• Re-biopsy of metastatic lesions should be performed if technically feasible to confirm histology and reassess biomarkers, as tumor biology may change from primary to metastatic disease 5, 6

Metastatic TNBC Treatment

• For PD-L1-positive disease, the American Society of Clinical Oncology recommends pembrolizumab plus chemotherapy as the preferred first-line regimen, providing significant survival benefit with median OS of 23.0 versus 16.1 months (HR 0.73; P=0.0093) 7, 8, 9
• For germline BRCA-mutated disease, the National Comprehensive Cancer Network recommends PARP inhibitors rather than chemotherapy in the first-through third-line setting, as they are superior to standard chemotherapy options 7, 8
• Single-agent chemotherapy is preferred for first-line treatment in PD-L1-negative and gBRCA wild-type disease to minimize toxicity 8
• The European Society for Medical Oncology recommends taxanes (paclitaxel or docetaxel) as preferred first-line options if not previously used in the adjuvant setting 8

Treatment Considerations

• Immune checkpoint inhibitors may be considered as monotherapy in further lines in case of high PD-L1 positivity and no previous exposure to ICI 7, 8, 9
• Chemotherapy should be maintained until the occurrence of disease progression or limiting toxicities 8

Management of Large Triple-Negative Breast Cancer After Neoadjuvant Therapy

Surgical Management

• The National Comprehensive Cancer Network recommends modified radical mastectomy as the standard surgical approach when breast-conserving surgery is not feasible after neoadjuvant therapy for large triple-negative breast cancer 10, 11
• Lumpectomy with level I/II axillary dissection is preferred if the tumor has downsized sufficiently after neoadjuvant therapy to allow breast conservation with acceptable cosmetic outcome 11
• Mastectomy with axillary staging is indicated for large tumors where adequate downsizing has not occurred, or where breast conservation would result in poor cosmetic outcome 10, 11
• The surgical decision should be made based on residual tumor extent assessed by breast MRI, which is the most accurate modality for evaluating response 12

Post-Mastectomy Radiation Therapy Indications

• The American Society of Clinical Oncology and the European Society for Medical Oncology recommend that radiation therapy decisions should be individualized based on the initial tumor stage at presentation and baseline nodal status, not solely on post-neoadjuvant pathologic findings 10, 13
• The St. Gallen 2023 consensus provides clear guidance for radiation after neoadjuvant therapy based on risk categories, with the highest-risk group (clinically node-positive at baseline with residual nodal involvement after neoadjuvant treatment) receiving comprehensive regional nodal radiation 10, 13

Radiation Therapy

• The National Comprehensive Cancer Network recommends comprehensive regional nodal radiation including level 1-3 axillary nodes, supraclavicular nodes, and internal mammary nodes for patients with clinically node-positive disease at baseline with residual nodal involvement after neoadjuvant treatment 10, 13
• Exclusive level 1-2 axillary radiation therapy may be considered for patients with clinically node-negative disease at baseline with no residual tumor in lymph nodes after neoadjuvant therapy 10, 13
• Chest wall radiation is mandatory when radiation is indicated, and supraclavicular and internal mammary nodes should be included for high-risk patients (initially clinically node-positive or with residual nodal disease) 10, 13

Evidence Supporting Radiation After Neoadjuvant Therapy

• The Early Breast Cancer Trialists' Collaborative Group meta-analysis found benefit from regional nodal radiation without increased risk for non-breast cancer mortality in patients receiving effective systemic therapy 10, 13

Treatment of Stage 4 Triple-Negative Breast Cancer

First-Line Treatment Algorithm

• The National Comprehensive Cancer Network recommends pembrolizumab plus chemotherapy for PD-L1-positive disease (CPS ≥10) and PARP inhibitors for germline BRCA1/2 mutations, with single-agent chemotherapy for PD-L1-negative disease without BRCA mutations 14
• For PD-L1-positive disease, pembrolizumab plus chemotherapy provides significant survival benefit with median OS of 23.0 versus 16.1 months (HR 0.73; P=0.0093) 14
• Atezolizumab plus albumin-bound paclitaxel demonstrates improved PFS (7.5 vs 5 months; HR 0.62) and OS (25 vs 15.5 months; HR 0.62) in PD-L1-positive tumors with ≥1% tumor-infiltrating immune cells 14

Immediate Testing Requirements

• The National Comprehensive Cancer Network recommends PD-L1 testing using an FDA-approved assay to determine eligibility for immunotherapy 14
• Germline BRCA1/2 mutation testing is recommended to identify candidates for PARP inhibitors 14, 15

Treatment Options

• For germline BRCA1/2-mutated disease, PARP inhibitors (olaparib or talazoparib) are preferred over chemotherapy, with median PFS of 7.0 months vs 4.2 months with chemotherapy (HR 0.58; P<0.001) for olaparib 14
• Platinum agents (cisplatin or carboplatin) are preferred alternatives if PARP inhibitors are unavailable or contraindicated, with the TNT trial demonstrating carboplatin superiority over docetaxel in BRCA-mutated patients (ORR 68.0% vs 33.3%; P=0.03) 14, 15

Second-Line and Beyond

• Platinum agents (if not previously used) are an alternative second-line option 15
• Capecitabine, eribulin, and gemcitabine are also alternative second-line options 14

Duration of Treatment

• Continue chemotherapy until disease progression or limiting toxicities, and continue HER2-targeted therapy in any breast cancer subtype with germline BRCA1/2 mutations until progression or unacceptable toxicity 16